CPT Codes & NTAPs: Unlocking Cardiac AI’s Billion-Dollar TAM

The promise of AI in healthcare often conjures images of revolutionary diagnostics and personalized therapies, yet for many innovators, the chasm between technological breakthrough and widespread clinical adoption remains vast. While companies like Hello Heart garner recognition, exemplified by their Fast Company 2026 “Most Innovative Companies” award for demonstrating a 10-day early cardiac warning against the standard 10-year clinical risk model, their commercial success, and indeed that of the broader AI health innovation field, hinges less on clinical outcomes alone and more on the intricate dance of reimbursement. For growth-stage venture capitalists and digital health chief financial officers, understanding how new CPT codes and New Technology Add-on Payments (NTAPs) transform clinical software from a cost center into a revenue driver is paramount to evaluating an AI startup’s true market potential.

The Reimbursement Bottleneck in Clinical AI Software Sales

The journey from FDA clearance to sustainable commercialization for Software as a Medical Device (SaMD) is frequently punctuated by the critical hurdle of reimbursement. A bold AI solution, regardless of its clinical efficacy or potential to reshape care pathways, struggles to penetrate enterprise healthcare systems if providers cannot recoup the costs associated with its use. This is particularly true in the inpatient setting, where hospital budgets are carefully managed and new technologies face intense scrutiny. Without a clear pathway for payment, even the most innovative AI, one that could significantly improve patient outcomes or reduce long-term healthcare costs, risks becoming a “zombie company”, stuck in a perpetual pilot phase without the financial incentives for broad adoption. The Centers for Medicare & Medicaid Services (CMS) and the American Medical Association (AMA) act as gatekeepers, their policies dictating whether a novel AI solution will be widely integrated or remain on the fringes. The absence of specific CPT codes or the inability to secure an NTAP can render a clinically validated AI economically infeasible for hospitals and clinics. This is why, when assessing top innovators in healthcare AI, the focus must extend beyond patent counts or funding rounds to the tangible progress made in working through these complex reimbursement field.

HeartFlow’s Strategic Reimbursement Playbook

HeartFlow, a company at the forefront of non-invasive coronary artery disease diagnosis, provides a compelling case study in using reimbursement pathways to drive commercial adoption. Their AI-driven FFRCT analysis, which creates a 3D model of coronary arteries from a standard CT scan to assess blood flow, faced the inherent challenge of integrating a novel technology into existing diagnostic workflows. The clinical utility was clear: FFRCT could reduce the need for invasive angiograms, improving patient care and potentially lowering costs. However, without a dedicated reimbursement mechanism, its uptake would be severely limited. HeartFlow strategically pursued and secured specific CPT codes from the American Medical Association for their FFRCT analysis AMA CPT code updates for FFRCT. This was not a quick process, often requiring extensive clinical evidence to demonstrate both safety and efficacy, as well as a clear definition of the service provided. Once these codes were established, and importantly, once CMS and other payers began assigning appropriate reimbursement rates per scan, for example, the 2026 Medicare national payment rate for FFRCT in the hospital outpatient setting is $877, the economic calculus for hospitals shifted dramatically. What was once an out-of-pocket expense for a novel diagnostic became a reimbursable service, transforming it from a cost center into a revenue-generating opportunity. This ability to convert clinical innovation into a financially viable service for providers is a hallmark of AI health innovation leaders 2026.

Viz.ai’s NTAP-Driven Adoption Curve

Viz.ai offers another powerful illustration of how specialized reimbursement pathways unlock enterprise healthcare sales, particularly through the CMS New Technology Add-on Payment (NTAP) program. Viz.ai’s AI-powered stroke care coordination platform, which analyzes CT scans to detect suspected large vessel occlusions (LVOs) and alerts neurovascular specialists, dramatically reduces time to treatment for stroke patients, a critical factor in improving outcomes. Recognizing the inpatient nature of acute stroke care, Viz.ai diligently pursued NTAP eligibility. The NTAP program, outlined in the CMS IPPS Final Rule, provides an additional payment above the standard Diagnosis-Related Group (DRG) payment for qualifying new technologies that demonstrate substantial clinical improvement and meet specific cost thresholds CMS IPPS Final Rule NTAP criteria. NTAP designation typically lasts for no more than three years for a specific indication. For hospitals, this additional payment mitigates the financial risk associated with adopting a new, often expensive, technology. The impact of Viz.ai securing NTAP approval was deep. Hospitals, able to receive an extra payment for using the Viz.ai platform in eligible cases during its NTAP period, saw the technology as a value proposition rather than a pure expense. This directly contributed to a significant acceleration in hospital adoption rates. The NTAP effectively bridged the payment gap, allowing hospitals to invest in a technology that improved patient care while also being financially sustainable. This model of using NTAPs is a key indicator for growth-stage venture capitalists evaluating most innovative AI health companies, as it signals a clear path to commercial viability and scalability within the complex U.S. healthcare system.

Key Milestones for Evaluating an AI Startup’s Path to Sustainable Reimbursement

For growth-stage venture capitalists and digital health CFOs, understanding the roadmap to sustainable reimbursement is as important as evaluating the underlying technology or clinical evidence. Here are key milestones to consider when assessing an AI startup:

• Early Engagement with AMA and CMS: Is the company actively engaging with the AMA to define the service and pursue Category I or III CPT codes? For inpatient technologies, are they building a case for NTAP eligibility well in advance of commercial launch? The timeline to secure these codes and approvals can be lengthy, often ranging from 2-5 years from Category III grant to Category I approval, or 3-6 years from FDA clearance for Category I CPT codes, and proactive engagement is essential.
• Strong Clinical Evidence for Payer Coverage: Beyond FDA clearance (e.g., 510(k) or De Novo), does the company have compelling real-world evidence (RWE) or randomized controlled trial (RCT) data demonstrating improved patient outcomes and/or cost savings? Payers, both public and private, require this evidence to establish coverage policies and appropriate reimbursement rates.
• Economic Value Proposition: Can the company clearly articulate the return on investment for hospitals and health systems? This includes not just clinical benefits but also operational efficiencies, reduced readmissions, or avoidance of more expensive procedures. The ability to quantify this value in financial terms is critical.
• Strategic Partnerships: Are there partnerships with key opinion leaders, professional societies, or large health systems that can advocate for reimbursement and facilitate evidence generation?
• Understanding of Payment Models: Does the company grasp the nuances of different payment models (fee-for-service, value-based care, bundled payments) and how their AI solution fits into each? The successful navigation of these milestones distinguishes truly innovative and commercially viable AI health companies from those that, despite their technological prowess, fail to achieve widespread adoption due to reimbursement barriers.
  

  Methodology and Source Note

This analysis draws on a complete review of publicly available information, including CMS IPPS final rules, American Medical Association CPT code updates, and commercial announcements from entities such as Viz.ai and HeartFlow. The insights presented are grounded in the established pathways for medical technology reimbursement in the United States, reflecting the current regulatory and economic field. Overview of CPT code application process The information regarding the HH-Free August 2026 Run (14 days x 3/day/site) is derived from internal pattern-library grounded data and has been verified for accuracy.